Aug 25 2021
Vimian’s Interim Report for the second quarter of 2021
Continued strong organic growth and strengthened market positions in Q2
- Revenue increased by 229 per cent to EUR 39.4m (12.0), and organic revenue growth was 25 per cent
- Adjusted EBITA amounted to EUR 12.2m (3.6), corresponding to an adjusted EBITA margin of 30.8 per cent (29.7)
- Operating profit totalled EUR 1.6m (-1.6), including items affecting comparability of EUR -7.6m (-4.2)
- Earnings per share before and after dilution totalled EUR -0.01 (-0.00)
“We report strong organic growth of 25 per cent in the second quarter, where all business areas demonstrate continued expansion. Our MedTech segment has seen accelerated growth following continued solid demand and successful commercial initiatives. Specialty Pharma also showed strong and accelerating underlying organic growth, above the average for Vimian Group in the quarter. The Diagnostics segment had a quarter to quarter variation due to an exceptional first quarter boosted by backorder filling and distributor re-stocking. Veterinary Services is starting to see positive momentum as Europe is slowly reopening”, says Dr. Fredrik Ullman, CEO of Vimian Group.
Adjusted EBITA increased to EUR 12.2m (3.6) in the quarter and the adjusted EBITA margin increased to 30.8 per cent, compared to 29.7 per cent in the quarter last year.
“Our medium-term target of 35 per cent EBITA margin will see variations between quarters near-term as we continue to invest where opportunities arise, to drive profitable long-term growth”, says Dr. Fredrik Ullman, CEO of Vimian Group.
A telephone and web conference will be organised for investors, analysts and media, today at 09.30 (CET). The conference will be held in English and include a question and answer session.
To attend the telephone conference:
To attend the web conference:
Related presentation materials will be available at Vimian’s corporate website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.